| Literature DB >> 32067294 |
Nabil Tahiri1, Peter Fodran1, Dhineshkumar Jayaraman1, Jeffrey Buter1, Martin D Witte1, Tonatiuh A Ocampo2, D Branch Moody2, Ildiko Van Rhijn2,3, Adriaan J Minnaard1.
Abstract
In Mycobacterium tuberculosis, mycolic acids and their glycerol, glucose, and trehalose esters ("cord factor") form the main part of the mycomembrane. Despite their first isolation almost a century ago, full stereochemical evaluation is lacking, as is a scalable synthesis required for accurate immunological, including vaccination, studies. Herein, we report an efficient, convergent, gram-scale synthesis of four stereo-isomers of a mycolic acid and its glucose ester. Binding to the antigen presenting protein CD1b and T cell activation studies are used to confirm the antigenicity of the synthetic material. The absolute stereochemistry of the syn-methoxy methyl moiety in natural material is evaluated by comparing its optical rotation with that of synthetic material.Entities:
Keywords: CD1b; cross coupling; mycolic acid; total synthesis; tuberculosis
Mesh:
Substances:
Year: 2020 PMID: 32067294 PMCID: PMC7216993 DOI: 10.1002/anie.202000523
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Figure 2Overview of the four diastereomeric mycolic acids (1 a–d), glucose mycolates (32 a–d), and methyl esters (33 a–d).
Figure 1The structure of the major methoxy mycolic acid homologue.
Scheme 1Retrosynthetic analysis.
Scheme 2a. The synthesis of fragment A. a) DIBAL, CH2Cl2, −78 °C, 1 h; b) 4, THF/toluene (2:1), 75 °C, 16 h, (70 % over two steps); c) Et3SiH, Pd/C, acetone, 0 °C to rt, 6 h, (82 %); d) (COBr)2, 8, pyridine, CH2Cl2, 0 °C to rt, 3 h (94 %); e) Cy2BOTf, NEt3, THF, −78 °C, then 6, 16 h; f) 2 m HClaq, THF, rt, 2 h (55 % over two steps, 67 % yield brsm); g) TBSOTf, 2,6‐lutidine, CH2Cl2, 0 °C to rt, 3 h (94 %); h) 1‐hexadecene, 9‐BBN, Pd(PCy3)2 (10 mol %), K3PO4⋅H2O, THF, rt, 16 h (87 %); i) pyridine⋅HF, THF, 0 °C to rt, 4 h (95 %); j) DMP, CH2Cl2, rt 1 h (96 %). b. Synthesis of fragment B. a) NaH, 1,3‐diaminopropane, 70 °C, 1.5 h; b) TBDPSCl, CH2Cl2, 0 °C to rt, 16 h (86 % over two steps); c) n‐BuLi, paraformaldehyde, THF, 0 °C to rt, 16 h (70 %); d) NaBH4, Ni(OAc)2⋅4 H2O, H2, ethylenediamine, EtOH, rt, 15 min (73 %); e) 1,2‐dimethoxyethane, diethylzinc, diiodomethane, 16, CH2Cl2, −15 °C to rt, 16 h; f) PivCl, DMAP, pyridine, CH2Cl2, 0 °C to rt, 16 h; g) TBAF, THF, 0 °C to rt, 16 h ( 97 % over three steps); h) CBr4, PPh3, CH2Cl2, 0 °C to rt, 3 h (90 %).22 DIBAL=diisobutylaluminium hydride, THF=tetrahydrofurane, TBSOTf=tert‐Butyldimethylsilyltrifluoromethanesulfonate, 9‐BBN=9‐borabicyclo(3.3.1)nonane, DMP=Dess–Martin periodinane, TBDPSCl=tert‐Butyldiphenylsilyl chloride, PivCl=pivaloyl chloride, TBAF=tetrabutylammonium fluoride.
Scheme 3a) The synthesis of fragment C. a: MeLi⋅LiBr, Et2O, −78 °C, 4 h (92 %); b: LiAlH4, THF, 0 °C, 1 h (quant.); c: CBr4, PPh3, CH2Cl2, 0 °C to rt, 4 h (84 %); d: 9‐BBN, 1‐hexadecene, K3PO4, cat. Pd(PCy3)2, THF, 16 h (84 %); e: 2 m HClaq, THF, 95 °C, 16 h; f: NaH, tosylimidazole, THF, rt, 16 h (90 % over two steps); g: 26, CuCl (5 mol %), THF, −10 °C, 2 h (85 %); h: MeI, NaH, THF, rt, 16 h (95 %).22 b) The endgame synthesis. a: 9‐BBN, 1‐hexadecene, fragment B, K3PO4, Pd(PCy3)2 (7 mol %), THF, 16 h; b: LiAlH4, THF, 0 °C, 15 min (78 % over two steps); c: phenyl‐1H‐tetrazole‐5‐thiol, PPh3, DIAD, THF, 0 °C to rt, 1 h (96 %); d: H2O2 (30 %), (NH4)6Mo7O28⋅4 H2O, THF, EtOH, n‐BuOH, rt, 5 d (99 %); e: LiHMDS, fragment A, −35 °C, 1 h (90 %); f: flavine cat.,30 hydrazine hydrate, THF, EtOH, n‐BuOH, rt, 5–7 d (98 %); g: HF⋅pyridine, CHCl3, 0 °C, 2 h (99 %); h: n‐Bu4NOH, (1.5 m in water), THF, rt, 16 h (95 %).22 Tosylimidazole=p‐toluenesulfonylimidazole, DIAD=diisopropylazodicarboxylate, LiHMDS=lithium hexamethyldisilazane.
Figure 3Biological validation of synthetic glucose methoxy mycolates (a,c) and methoxy mycolic acids (b,d). Methods are provided in the Supporting Information.